why does nobody talk about MASH
why does nobody talk about MASH, and I want the answer with the reasoning attached rather than just the conclusion. What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote. It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to…
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost no
Disagreeing with this bit: that number comes from a different programme with a different population.
Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.
Biopsy-confirmed population or imaging-selected?
the titration in the trials was slow and deliberate
How fast was the escalation in that protocol?
Has anyone posted an independent purity result for this compound?
Sent a vial to Janoshik because there was nothing on file. 99.5% against a claimed 99.0%. First entry for this compound in my own log.
independent testing on this compound is very thin
Is that a weight number from a different programme?
phase 2 in liver disease is a different evidence question from weight
the weight numbers are secondary to what this is being developed for